Author
University of North Carolina at Chapel HillORCID 0000-0003-4799-6792Unclaimed ORCID profile · follow to get notified of new preprints
6 papers
Recent·Most cited
Frances M. Bashore, Sophia M. Min, Xiangrong Chen…·Alison D. Axtman
The paper identifies and characterizes a chemical probe for CDKL2, demonstrating its selectivity and biological impact in neurons and cancer cells.
Joseph A. Newman, Angeline E. Gavard, Nergis Imprachim…·David Harold Drewry
This study determines the structure of human brachyury, identifies DNA binding insights and a G177D variant, and discovers small molecule binders for potential cancer therapy.
Christopher R. M. Asquith, Michael P. East, Tuomo Laitinen…·Gary L. Johnson
The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.
Anna M. Castano, Margaux Silvestre, Carrow I. Wells…·Alison Donnelly Axtman
The paper develops specific CDKL5 inhibitors that do not affect GSK3β activity and shows their effects on synaptic function and LTP in rat hippocampal slices.
Frances Potjewyd, Joel K. Annor‐Gyamfi, Jeffrey Aubé…·Alison Donnelly Axtman
The paper compiles an annotated set of 171 small molecule modulators targeting 98 novel AD therapeutic proteins, serving as chemical tools for hypothesis validation.
Andrea I. Krahn, Carrow I. Wells, David Harold Drewry…·Alison Donnelly Axtman
The paper discusses the potential of kinase inhibitors for neurodegenerative diseases, highlighting the need for validated targets and strategies for drug discovery.